Charles Schwab’s Orchestra BioMed OBIO Stock Holding History

Charles Schwab’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.51M	Buy	349,544 +84,045	+32%	+$344K	﹤0.01%	2881
2026 Q1	$1.13M	Buy	265,499 +1,711	+0.6%	+$7.28K	﹤0.01%	2867
2025 Q4	$1.09M	Buy	263,788 +83,349	+46%	+$336K	﹤0.01%	2894
2025 Q3	$447K	Buy	180,439 +41,848	+30%	+$115K	﹤0.01%	3203
2025 Q2	$371K	Sell	138,591 -78,394	-36%	-$229K	﹤0.01%	3246
2025 Q1	$929K	Sell	216,985 -1,670	-0.8%	-$8.3K	﹤0.01%	2863
2024 Q4	$875K	Buy	218,655 +1,647	+0.8%	+$8.85K	﹤0.01%	2960
2024 Q3	$1.12M	Buy	217,008 +8,107	+4%	+$53K	﹤0.01%	2887
2024 Q2	$1.7M	Buy	208,901 +29,191	+16%	+$169K	﹤0.01%	2753
2024 Q1	$947K	Buy	179,710 +4,165	+2%	+$28.2K	﹤0.01%	2812
2023 Q4	$1.6M	Buy	175,545 +21,781	+14%	+$149K	﹤0.01%	2683
2023 Q3	$1.34M	Buy	153,764 +70,117	+84%	+$471K	﹤0.01%	2705
2023 Q2	$586K	Buy	83,647 +17,052	+26%	+$259K	﹤0.01%	2974
2023 Q1	$1.3M	Buy	+66,595	New	+$771K	﹤0.01%	2646

Other funds holding OBIO

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Charles Schwab's OBIO Position: Q2 2026 in Review

Charles Schwab increased its Orchestra BioMed (OBIO) stake by 32% in Q2 2026, buying an estimated $344K and bringing the position to 349,544 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #2881.

Charles Schwab first reported a position in OBIO in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.7M in Q2 2024. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

Charles Schwab held 349,544 shares of Orchestra BioMed worth $1.51M as of Q2 2026.
Charles Schwab bought 84,045 Orchestra BioMed shares in Q2 2026, an estimated $344K.
Orchestra BioMed made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2881 holding.
Charles Schwab first reported a position in Orchestra BioMed in Q1 2023 and has held it in 14 quarters since.
Charles Schwab's Orchestra BioMed position peaked at $1.7M in Q2 2024.
77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.